Abstract
Invariant natural killer T cells have been implicated in a number of autoimmune diseases. In this Review, the authors highlight recent advances in our understanding of distinct subsets of these cells and the immunoregulatory cytokines they produce, and discuss whether inducing differential cytokine responses in these cells could be exploited to develop cell-based therapies. Invariant natural killer T (iNKT) cells are an innate T-cell lineage known to recognize a range of endogenously derived and exogenously derived glycolipid antigens. Advances in our understanding of this T-cell subset have enabled researchers to investigate the immunomodulatory activity of iNKT cell ligands in experimental models of diseases such as cancer, allergy and chronic inflammatory joint disease. To a large extent, the ability of iNKT cells to regulate such disease models has been ascribed to their capacity to promote a polarized cytokine environment, which is understood to skew adaptive immune responses. In this Review, we discuss the current understanding of how iNKT-cell polarization is regulated and relate this basic theory to the proposed role for iNKT cells in models of rheumatologic disease.

This publication has 119 references indexed in Scilit: